Table Info

Table 2.

Comparisons of the different studies analysing the signification of aPZ-Ab on the thrombotic risk

References	Controls (n)	Cut-off (AU/mL)	Patients	Conclusions
[18]	82 donors from the blood bank	1 (for IgG or IgM)*	50 with arterial thrombosis, 64 with venous thrombosis	aPZ-Ab (IgG) higher in patients with arterial thrombosis, but the vast majority < 1 AU/mL
[19]	33 healthy volunteers	IgG: 75th pctl: 4.4 IgM: 75th pctl: 5.3	102 patients with lupus anticoagulant (LAC; 62 with thrombosis, 33 asymptomatic)	IgM > 75th pctl more frequent in the patient group. Similar frequency of elevated aPZ-Ab (IgG or IgM) in patients with and without thrombosis
[20]	59 healthy volunteers	IgG: 95th pctl: 10 IgM: 95th pctl: 10	86 consecutive patients with anticardiolipin (aCL) antibodies	Frequency aPZ-Ab in the patient group: 40.7% The frequency of aPZ-Ab increases in patients with a double or triple positivity of antiphospholipid antibodies Higher frequency of aPZ-Ab in patients with LAC (57.7%) than in patients without LAC (25.6%) Similar frequency of elevated aPZ-Ab (IgG or IgM) in patients with and without thrombosis High frequency of aPZ-Ab in patients with foetal loss
[21]	23 healthy volunteers	NR	21 with central retinal vein occlusion	No significant difference in the frequency of aPZ-Ab between patients and cases

*: whereas all the studies used the same commercial assay, this one used a homemade assay. NR: not-reported

Declarations

Acknowledgments

The authors thank Polly Gobin for her editorial assistance and Dr. Jean Amiral for helpful discussion.

Author contributions

TP and SZC: Resources, Visualization, Writing—review & editing. THA: Resources, Writing—review & editing. MV: Conceptualization, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Broze GJ Jr, Miletich JP. Human protein Z. J Clin Invest. 1984;73:933–8. [DOI] [PubMed] [PMC]

Sejima H, Hayashi T, Deyashiki Y, Nishioka J, Suzuki K. Primary structure of vitamin K-dependent human protein Z. Biochem Biophys Res Commun. 1990;171:661–8. [DOI] [PubMed]

Ichinose A, Takeya H, Espling E, Iwanaga S, Kisiel W, Davie EW. Amino acid sequence of human protein Z, a vitamin K-dependent plasma glycoprotein. Biochem Biophys Res Commun. 1990;172:1139–44. [DOI] [PubMed]

Han X, Fiehler R, Broze GJ Jr. Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci U S A. 1998;95:9250–5. [DOI] [PubMed] [PMC]

Han X, Fiehler R, Broze GJ Jr. Characterization of the protein Z-dependent protease inhibitor. Blood. 2000;96:3049–55. [DOI] [PubMed]

Tabatabai A, Fiehler R, Broze GJ Jr. Protein Z circulates in plasma in a complex with protein Z-dependent protease inhibitor. Thromb Haemost. 2001;85:655–60. [DOI] [PubMed]

Qureshi SH, Lu Q, Manithody C, Yang L, Rezaie AR. Characterization of the protein Z-dependent protease inhibitor interactive-sites of protein Z. Biochim Biophys Acta. 2014;1844:1631–7. [DOI] [PubMed] [PMC]

Rezaie AR, Bae JS, Manithody C, Qureshi SH, Yang L. Protein Z-dependent protease inhibitor binds to the C-terminal domain of protein Z. J Biol Chem. 2008;283:19922–6. [DOI] [PubMed] [PMC]

Wei Z, Yan Y, Carrell RW, Zhou A. Crystal structure of protein Z-dependent inhibitor complex shows how protein Z functions as a cofactor in the membrane inhibition of factor X. Blood. 2009;114:3662–7. [DOI] [PubMed] [PMC]

10.

Huang X, Swanson R, Broze GJ, Olson ST. Kinetic characterization of the protein Z-dependent protease inhibitor reaction with blood coagulation factor Xa. J Biol Chem. 2008;283:29770–83. [DOI] [PubMed] [PMC]

11.

Vasse M. Protein Z, a protein seeking a pathology. Thromb Haemost. 2008;100:548–56. [DOI] [PubMed]

12.

Sofi F, Cesari F, Abbate R, Gensini GF, Broze G Jr, Fedi S. A meta-analysis of potential risks of low levels of protein Z for diseases related to vascular thrombosis. Thromb Haemost. 2010;103:749–56. [DOI] [PubMed] [PMC]

13.

Gris JC, Amadio C, Mercier E, Lavigne-Lissalde G, Déchaud H, Hoffet M, et al. Anti-protein Z antibodies in women with pathologic pregnancies. Blood. 2003;101:4850–2. [DOI] [PubMed]

14.

Gris JC, Quéré I, Dechaud H, Mercier E, Pinçon C, Hoffet M, et al. High frequency of protein Z deficiency in patients with unexplained early fetal loss. Blood. 2002;99:2606–8. [DOI] [PubMed]

15.

Sater MS, Finan RR, Al-Hammad SA, Mohammed FA, Issa AA, Almawi WY. High frequency of anti-protein Z IgM and IgG autoantibodies in women with idiopathic recurrent spontaneous miscarriage. Am J Reprod Immunol. 2011;65:526–31. [DOI] [PubMed]

16.

Erez O, Romero R, Vaisbuch E, Mazaki-Tovi S, Kusanovic JP, Chaiworapongsa T, et al. Maternal anti-protein Z antibodies in pregnancies complicated by pre-eclampsia, SGA and fetal death. J Matern Fetal Neonatal Med. 2009;22:662–71. [DOI] [PubMed] [PMC]

17.

Kusanovic JP, Espinoza J, Romero R, Hoppensteadt D, Nien JK, Kim CJ, et al. Plasma protein Z concentrations in pregnant women with idiopathic intrauterine bleeding and in women with spontaneous preterm labor. J Matern Fetal Neonatal Med. 2007;20:453–63. [DOI] [PubMed] [PMC]

18.

Pardos-Gea J, Ordi-Ros J, Serrano S, Balada E, Nicolau I, Vilardell M. Protein Z levels and anti-protein Z antibodies in patients with arterial and venous thrombosis. Thromb Res. 2008;121:727–34. [DOI] [PubMed]

19.

Sailer T, Vormittag R, Koder S, Quehenberger P, Kaider A, Pabinger I. Clinical significance of anti-protein Z antibodies in patients with lupus anticoagulant. Thromb Res. 2008;122:153–60. [DOI] [PubMed]

20.

Andriamandimbisoa TH, Kahn JE, Bourdain F, François D, Vasse M. High frequency of anti-protein Z antibodies in patients with anticardiolipin antibodies. Immunobiology. 2018;223:772–6. [DOI] [PubMed]

21.

Tea S, Barrali M, Racadot E, Delbosc B. Evaluation of coagulopathies and fibrinolytic abnormalities in central retinal vein occlusion in patients under 60 years of age. J Fr Ophtalmol. 2013;36:5–11. French. [DOI] [PubMed]

22.

Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev. 2008;7:272–7. [DOI] [PubMed]

23.

Nien JK, Romero R, Hoppensteadt D, Erez O, Espinoza J, Soto E, et al. Pyelonephritis during pregnancy: a cause for an acquired deficiency of protein Z. J Matern Fetal Neonatal Med. 2008;21:629–37. [DOI] [PubMed] [PMC]

24.

Bartolini L, Gentilomo C, Sartori S, Calderone M, Simioni P, Laverda AM. Varicella and stroke in children: good outcome without steroids. Clin Appl Thromb Hemost. 2011;17:E127–30. [DOI] [PubMed]

25.

Knight JS, Caricchio R, Casanova JL, Combes AJ, Diamond B, Fox SE, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021;131:e154886. [DOI] [PubMed] [PMC]

26.

Amiral J, Seghatchian J. Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes. Transfus Apher Sci. 2023;62:103625. [DOI] [PubMed] [PMC]

27.

Odorczuk M, Keil LB, DeBari VA. Binding of complement component C1q to anti-β2 glycoprotein I antibodies from patients with antiphospholipid syndrome. Inflamm Res. 1999;48:524–6. [DOI] [PubMed]

28.

Tedesco F, Borghi MO, Gerosa M, Chighizola CB, Macor P, Lonati PA, et al. Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications. Front Immunol. 2018;9:1388. [DOI] [PubMed] [PMC]

29.

Scambi C, Ugolini S, Tonello M, Bortolami O, De Franceschi L, Castagna A, et al. Complement activation in the plasma and placentas of women with different subsets of antiphospholipid syndrome. Am J Reprod Immunol. 2019;82:e13185. [DOI] [PubMed]

30.

Gris JC, Mercier E, Quéré I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103:3695–9. [DOI] [PubMed]

31.

D’Ippolito S, Di Simone N, Di Nicuolo F, Castellani R, Caruso A. Antiphospholipid antibodies: effects on trophoblast and endothelial cells. Am J Reprod Immunol. 2007;58:150–8. [DOI] [PubMed]

32.

Richani K, Romero R, Kim YM, Cushenberry E, Soto E, Han YM, et al. Tissue microarray: an effective high-throughput method to study the placenta for clinical and research purposes. J Matern Fetal Neonatal Med. 2006;19:509–15. [DOI] [PubMed]

33.

Vasse M, Denoyelle C, Corbière C, Litzler PY, Legrand E, Vannier JP. Human endothelial cells synthesize protein Z, but not the protein Z dependent inhibitor. Thromb Haemost. 2006;95:519–23. [DOI] [PubMed]

34.

Sierko E, Wojtukiewicz MZ, Zimnoch L, Tokajuk P, Ostrowska-Cichocka K, Kisiel W. Co-localization of protein Z, protein Z-dependent protease inhibitor and coagulation factor X in human colon cancer tissue: implications for coagulation regulation on tumor cells. Thromb Res. 2012;129:e112–8. [DOI] [PubMed]

35.

Matsumoto M, Tachibana D, Nobeyama H, Nakano A, Nakai Y, Nakayama M, et al. Protein S deposition at placenta: a possible role of protein S other than anticoagulation. Blood Coagul Fibrinolysis. 2008;19:653–6. [DOI] [PubMed]

36.

Sato Y, Sugi T, Sakai R. Antigenic binding sites of anti-protein S autoantibodies in patients with recurrent pregnancy loss. Res Pract Thromb Haemost. 2018;2:357–65. [DOI] [PubMed] [PMC]

37.

Payne SG, Brindley DN, Guilbert LJ. Epidermal growth factor inhibits ceramide-induced apoptosis and lowers ceramide levels in primary placental trophoblasts. J Cell Physiol. 1999;180:263–70. [DOI] [PubMed]

38.

Dörner T, Hoppe B, Salama A, Pruss A, Kiesewetter H. Antibodies against protein Z and fetal loss: current perspectives. Clin Exp Med. 2005;5:50–4. [DOI] [PubMed]

39.

Visser M, Heitmeier S, Ten Cate H, Spronk HMH. Role of factor XIa and plasma kallikrein in arterial and venous thrombosis. Thromb Haemost. 2020;120:883–993. [DOI] [PubMed]

40.

Steffano B, Forastiero R, Martinuzzo M, Kordich L. Low plasma protein Z levels in patients with antiphospholipid antibodies. Blood Coagul Fibrinolysis. 2001;12:411–2. [DOI] [PubMed]

41.

Forastiero RR, Martinuzzo ME, Lu L, Broze GJ. Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor. J Thromb Haemost. 2003;1:1764–70. [DOI] [PubMed]

42.

McColl MD, Deans A, Maclean P, Tait RC, Greer IA, Walker ID. Plasma protein Z deficiency is common in women with antiphospholipid antibodies. Br J Haematol. 2003;120:913–4. [DOI]

43.

Bretelle F, Arnoux D, Shojai R, D’Ercole C, Sampol J, Dignat F, et al. Protein Z in patients with pregnancy complications. Am J Obstet Gynecol. 2005;193:1698–702. [DOI] [PubMed]

44.

Paidas MJ, Ku DH, Lee MJ, Manish S, Thurston A, Lockwood CJ, et al. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. J Thromb Haemost. 2005;3:497–501. [DOI] [PubMed]